MA52286A - Dérivés de pyrazo-tétrahydroisoquinoléine en tant que modulateurs positifs du récepteur d1 de la dopamine - Google Patents

Dérivés de pyrazo-tétrahydroisoquinoléine en tant que modulateurs positifs du récepteur d1 de la dopamine

Info

Publication number
MA52286A
MA52286A MA052286A MA52286A MA52286A MA 52286 A MA52286 A MA 52286A MA 052286 A MA052286 A MA 052286A MA 52286 A MA52286 A MA 52286A MA 52286 A MA52286 A MA 52286A
Authority
MA
Morocco
Prior art keywords
tetrahydroisoquinolein
pyrazo
dopamine
receptor
derivatives
Prior art date
Application number
MA052286A
Other languages
English (en)
Inventor
David Andrew Coates
Junliang Hao
Darryl Wayne Hilliard
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA52286A publication Critical patent/MA52286A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA052286A 2018-04-20 2019-04-17 Dérivés de pyrazo-tétrahydroisoquinoléine en tant que modulateurs positifs du récepteur d1 de la dopamine MA52286A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862660622P 2018-04-20 2018-04-20

Publications (1)

Publication Number Publication Date
MA52286A true MA52286A (fr) 2021-05-12

Family

ID=66324031

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052286A MA52286A (fr) 2018-04-20 2019-04-17 Dérivés de pyrazo-tétrahydroisoquinoléine en tant que modulateurs positifs du récepteur d1 de la dopamine

Country Status (29)

Country Link
US (1) US10611751B2 (fr)
EP (1) EP3781560B1 (fr)
JP (1) JP7083916B2 (fr)
KR (1) KR102520872B1 (fr)
CN (1) CN111971282B (fr)
AR (1) AR114467A1 (fr)
AU (1) AU2019256350B2 (fr)
BR (1) BR112020019934A2 (fr)
CA (1) CA3097692C (fr)
CL (1) CL2020002697A1 (fr)
CO (1) CO2020012678A2 (fr)
CR (1) CR20200481A (fr)
EA (1) EA202092146A1 (fr)
EC (1) ECSP20066271A (fr)
ES (1) ES2927142T3 (fr)
IL (1) IL278045B2 (fr)
JO (1) JOP20200263B1 (fr)
MA (1) MA52286A (fr)
MX (1) MX2020010914A (fr)
MY (1) MY197645A (fr)
NZ (1) NZ767900A (fr)
PE (1) PE20201151A1 (fr)
PH (1) PH12020551713A1 (fr)
SA (1) SA520420382B1 (fr)
SG (1) SG11202009938TA (fr)
TW (1) TWI725408B (fr)
UA (1) UA125271C2 (fr)
WO (1) WO2019204418A1 (fr)
ZA (1) ZA202006439B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY210361A (en) 2019-07-01 2025-09-13 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
US12358890B2 (en) 2019-07-01 2025-07-15 UCB Biopharma SRL Substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator
PL4200280T3 (pl) * 2020-10-07 2024-05-20 Eli Lilly And Company Pochodne fenylo-3,4-dihydroizochinolin-2(1h)-ylo-etan-1-onu jako dodatnie modulatory allosteryczne receptora dopaminy d1
US20240043400A1 (en) * 2020-12-03 2024-02-08 UCB Biopharma SRL Octahydroisoquinolinyl Derivatives
WO2022129303A1 (fr) 2020-12-18 2022-06-23 UCB Biopharma SRL Dérivés de dihydroisoquinolinyle

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2061972T3 (es) 1988-02-19 1994-12-16 Smithkline Beecham Farma 1,2,3,4-tetrahidroisoquinoleinas, procedimiento para su preparacion y su uso como agonistas kapa-receptores.
US5236934A (en) 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
CA2408486A1 (fr) 2000-05-11 2001-11-15 Bristol-Myers Squibb Company Analogues de tetrahydroisoquinoline servant de secretagogues d'hormones de croissance
US7601739B2 (en) 2003-08-08 2009-10-13 Virgina Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases
AR095883A1 (es) 2013-04-18 2015-11-18 Astellas Pharma Inc Compuestos de acetamida heterocíclica
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
WO2016055482A1 (fr) 2014-10-08 2016-04-14 Ucb Biopharma Sprl Dérivés d'isoindoline
BR112017007123B1 (pt) 2014-10-08 2023-01-31 Ucb Biopharma Sprl Composto representado pela fórmula (i-a), ou um seu sal farmaceuticamente aceitável, uso de um composto de fórmula (ia) e composição farmacêutica
AR105025A1 (es) 2015-06-19 2017-08-30 Astellas Pharma Inc Compuesto de imidazodiazepina
AR106332A1 (es) * 2015-10-23 2018-01-03 Lilly Co Eli Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona
WO2017178377A1 (fr) 2016-04-13 2017-10-19 Ucb Biopharma Sprl Dérivés de tétrahydroisoquinoléine
EP3418270A1 (fr) 2017-06-19 2018-12-26 Universidad Complutense De Madrid Nouveaux biphénylsulfoximines comme modulateurs allostériques du récepteur de la dopamine d1
WO2019173437A1 (fr) 2018-03-06 2019-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulateurs allostériques positifs du récepteur de la dopamine 1 et procédé d'utilisation associé

Also Published As

Publication number Publication date
JP7083916B2 (ja) 2022-06-13
IL278045A (en) 2020-11-30
EP3781560B1 (fr) 2022-08-24
TW202003486A (zh) 2020-01-16
IL278045B1 (en) 2023-05-01
US10611751B2 (en) 2020-04-07
UA125271C2 (uk) 2022-02-09
MY197645A (en) 2023-06-30
KR20200132948A (ko) 2020-11-25
ES2927142T3 (es) 2022-11-02
ZA202006439B (en) 2024-06-26
CO2020012678A2 (es) 2020-10-30
CN111971282B (zh) 2024-03-19
CA3097692A1 (fr) 2019-10-24
EA202092146A1 (ru) 2021-01-25
IL278045B2 (en) 2023-09-01
TWI725408B (zh) 2021-04-21
BR112020019934A2 (pt) 2021-01-05
WO2019204418A1 (fr) 2019-10-24
PE20201151A1 (es) 2020-10-26
NZ767900A (en) 2023-06-30
AU2019256350B2 (en) 2021-04-22
AR114467A1 (es) 2020-09-09
US20190322639A1 (en) 2019-10-24
JOP20200263B1 (ar) 2024-04-18
EP3781560A1 (fr) 2021-02-24
CL2020002697A1 (es) 2021-02-19
CN111971282A (zh) 2020-11-20
MX2020010914A (es) 2021-01-08
PH12020551713A1 (en) 2021-07-26
JOP20200263A1 (ar) 2020-10-15
ECSP20066271A (es) 2020-11-30
AU2019256350A1 (en) 2020-09-24
JP2021518853A (ja) 2021-08-05
KR102520872B1 (ko) 2023-04-13
SA520420382B1 (ar) 2022-08-04
CA3097692C (fr) 2024-02-20
CR20200481A (es) 2020-11-18
SG11202009938TA (en) 2020-11-27

Similar Documents

Publication Publication Date Title
MA52286A (fr) Dérivés de pyrazo-tétrahydroisoquinoléine en tant que modulateurs positifs du récepteur d1 de la dopamine
MA49128A (fr) Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2
EP3356356A4 (fr) Composés utiles en tant que modulateurs de trpm8
MA43512A (fr) Composés hétérocycliques utiles en tant que modulateurs du tnf alpha
MA49126A (fr) Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2
MA49055A (fr) Dérivés d'imidazoles pentacycliques fusionnés en tant que modulateurs de l'activité de tnf
EP3347372A4 (fr) Macrocycles peptidomimétiques en tant que modulateurs de mcl-1
MA43864A (fr) Utilisation de dérivés de thiohydantoin substitué en tant qu'antagonistes des récepteurs d'androgènes
IL281492A (en) Modulators of pnpla3 expression
MA48987A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA44498A (fr) Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
EP3328379A4 (fr) Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines
MA55046A (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
MA47370A (fr) Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines
MA48943A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
EP3755311A4 (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
EP3654987A4 (fr) Utilisation de dérivés aminoalkylbenzothiazépine
EP3509588A4 (fr) Composés bicycliques utiles en tant que modulateurs du gpr120
IL283967A (en) Modulators of hsd17b13 expression
IL283282B (en) Compounds and synthetic methods for the preparation of retinoid x receptor-specific retinoids
MA41341A (fr) Dérivés indole utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
EP2958564A4 (fr) Composés hétéro-aromatiques en tant que modulateurs de pi3 kinase
PL3625224T3 (pl) Pochodne n-podstawionego indolu
EP2976077A4 (fr) Benzimidazoles substitués en tant que modulateurs d'un récepteur de nociceptine
EP3758704A4 (fr) Modulateurs de l'expression d'irf4